# The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.

> **NCT02336607** · NA · COMPLETED · sponsor: **AstraZeneca** · enrollment: 529 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Felodipine tablet (Plendil) alone
- **DRUG:** Felodipine tablet (Plendil)+Hydrochlorothiazide
- **DRUG:** Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)
- **DRUG:** Felodipine tablets (Plendil)+Lisinopril (Zestril)

## Key facts

- **NCT ID:** NCT02336607
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2006-06
- **Final completion:** 2006-08
- **Target enrollment:** 529 (ACTUAL)
- **Last updated:** 2015-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02336607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02336607, "The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT02336607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*